';
Effective September 1, 2025, there is a rate change in the OBRA Waiver and Act 150 Program for the monthly Financial Management Services (FMS) procedure code W7341. The new FMS monthly ongoing rate is $101.43, starting with the September 1, 2025, date of service.
Home and Community Services Information System (HCSIS) service plans are being updated to reflect the September 1 effective date. Service Coordinators do not need to make any service plan updates for this rate change, as an HCSIS system-wide update is being deployed to make the necessary service data rate updates on the impacted service plans.
If you have any questions, please contact the Office of Long-Term Living Provider Inquiry Line at 800-932-0939, Option 2, Monday through Friday from 9:00 am – 12:00 pm or 1:00 pm – 4:00 pm.
Today, August 13, the Office of Developmental Programs (ODP) held the first Supports Coordination Organization Performance-Based Contracting SCO Summit. The PowerPoint is available here. All sessions will be recorded and available on MyODP.
Additional Summits, PAS Trainings, and VOHs will be held on the following dates:
The Office of Developmental Programs (ODP) has released additional information on upcoming employment symposiums as well as an agenda for each symposium. These symposiums are specifically for employers and will feature:
Below are the event dates and locations:
These sessions are targeted toward businesses in your community. ODP requests your assistance with sharing this information with your business contacts who are looking to hire.

The Office of Developmental Programs (ODP) has shared this important announcement from the U. S. Food and Drug Administration (FDA).
FDA MedWatch — DermaKleen, Dermasarra, Kleenfoam, and Perigiene Products by DermaRite Industries
DermaRite Industries is recalling the below products due to microbial contamination identified as Burkholderia cepacia.
Risk Statement:
Burkholderia cepacia complex (BCC) in these products may result in serious and life-threatening infections. The contaminated products may be used by immunosuppressed individuals or by people attending to immunosuppressed individuals. In healthy individuals with minor skin lesions, the use of the product will more likely result in local infections, whereas in immunocompromised individuals the infection is more likely to spread into blood stream leading to life-threatening sepsis.
The recalled products were distributed nationwide in the United States and in Puerto Rico.
To date, DermaRite has not received any reports of adverse events related to this recall.
Background:
Recommendations:
For more information about this recall and specific product number, visit the FDA’s website.
Article reprinted with permission from OPEN MINDS. To sign up for a free OPEN MINDS news feed on https://www.openminds.com/market-intelligence/, go to https://www.openminds.com/membership/.

A performance-based contracting (PBC) forum is being provided on September 10, 2025, from 2:00 pm – 3:30 pm, to support provider preparedness. This forum aimed at residential providers. Register here to attend.
Topics of discussion include: